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Abstract 
Non-alcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver 
transplantation (LT) in the US. We aimed to determine the temporal trend behind the rise in 
obesity and NASH-related additions to the LT waitlist in the US and make projections for future 
NASH burden on the LT waitlist. We used data from the Organ Procurement and 
Transplantation Network database from 2000-2014 to obtain the number of NASH-related LT 
waitlist additions. The obese population in the US from 2000-2014 was estimated using data 
from the US Census Bureau and the National Health and Nutrition Examination Survey. Based 
on obesity trends, we established a time lag between obesity prevalence and NASH-related 
waitlist additions. We used data from the US Census Bureau on population projections from 
2016-2030 to forecast obesity estimates and NASH-related LT waitlist additions. From 2000-
2014, the proportion of obese individuals significantly increased 44.9% and the number of 
NASH-related annual waitlist additions increased from 391 to 1605. Increase in obesity 
prevalence was strongly associated with LT waitlist additions 9 years later in derivation and 
validation cohorts (R2=0.9). Based on these data, annual NASH-related waitlist additions are 
anticipated to increase by 55.4% (1,354 to 2,104) between 2016 and 2030. There is significant 
regional variation in obesity rates and in the anticipated increase in NASH-related waitlist 
additions (p<0.01). Conclusion: We project a marked increase in demand for LT for NASH 
given population obesity trends. Continued public health efforts to curb obesity prevalence are 
needed to reduce the projected future burden of NASH. 
 
 
 
 
  
Page 3 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
4 
 
 
Introduction 
Non-alcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver 
transplantation (LT) in the US.(1, 2) While hepatitis C infection is currently the most common 
indication for LT in the US, the proportion of patients who require LT for hepatitis C is projected 
to decrease in coming years, primarily due to increased hepatitis C screening efforts among at-
risk groups and the advent of highly effective anti-viral therapies for hepatitis C.(3) In contrast, 
given the historic rise obesity in the US, the incidence of NASH is expected to increase; 
however, we lack granular projections of the future burden of NASH cirrhosis and NASH-related 
complications in the US. 
Obesity is highly prevalent in the US, with recent estimates indicating 38% of adults with a body 
mass index (BMI) greater than 30.(4) Obesity is associated with the development of the 
metabolic syndrome, which includes dyslipidemia, hypertension, insulin resistance, and hepatic 
steatosis.(5) Those with hepatic steatosis can develop NASH, which is characterized by necro-
inflammation, which, in turn, leads to hepatic fibrosis and increased risk of development of 
hepatocellular carcinoma (HCC).(6, 7) Thus NASH will become a leading indication for LT both 
in the US and internationally in other countries with rising obesity prevalence.(3, 4, 8) This has 
several healthcare resource implications, as the population of patients with NASH-related 
cirrhosis grows and subsequently develops cirrhosis-related complications (i.e. hepatic 
decompensation and HCC) that require high resource care and consideration of LT.  
 Duration of obesity and presence of the metabolic syndrome in an individual patient can 
increase the risk of development of NASH-related cirrhosis and HCC.(9, 10) From an 
epidemiologic perspective, however, the temporal relationship between obesity prevalence in 
the population and the rise in NASH-related cirrhosis and decompensation is unclear. Several 
developed and developing countries worldwide are seeing increases in obesity prevalence(11), 
however the lag in years between development of obesity in the population and increases in the 
proportion of patients that present for LT due to NASH remains poorly characterized. Thus, in 
this analysis we aimed to determine the population-based temporal relationship between obesity 
and NASH-related cirrhosis requiring liver transplantation listing in the US. We also aimed to 
project the future burden of NASH-related cirrhosis requiring LT waitlist addition in the US based 
on historical and projected US population obesity prevalence. 
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Methods 
Data Sources 
Waiting List Data 
We analyzed data from the Organ Procurement and Transplantation Network (OPTN) database 
from 2000-2014 to obtain the historical number of additions to the waiting list per year due to 
NASH.(12) From 2000-2003 there were no primary codes due to NASH, thus we relied on the 
“other” field in identifying NASH diagnoses. If the primary diagnosis was “other” we included 
those individuals who had “NASH” or “NAFLD” included in the text field. Previous analyses have 
shown that a significant proportion of patients diagnosed with cryptogenic cirrhosis likely 
represented undiagnosed NASH cirrhosis, so we used a modified definition of NASH that 
includes obese cryptogenic patients, based on a previously published algorithm.(1) We included 
all adult waiting list additions between 18 and 74 years of age whose body mass index (BMI) 
was less than 60 kg/m2. The 60 kg/m2 cutoff was used because of the low likelihood of 
transplant of extremely obese individuals. For our regional analyses, NASH additions to the 
waiting list per year were categorized into 11 regions established by United Network for Organ 
Sharing (UNOS).  
 
Historical National Population Obesity Prevalence Data 
Data from the Continuous National Health and Nutrition Examination Survey (NHANES) from 
1999 to 2014 were used to obtain estimates of national obesity prevalence per year.(13) The 
Continuous NHANES data on BMI are directly measured and collected in two-year cycles, thus 
we divided each cycle according to the time period the data was collected. We assumed data 
collected from November 1 through April 30 were representative of the first year of the cycle and 
data collected from May 1 to October 31 were representative of the second year of the cycle. 
NHANES entries with any missing BMI data were excluded for this calculation (n=869; 2.1%). 
We stratified the data from the Continuous NHANES data according to obesity categories based 
on the following obesity strata (class I-III): 30 to <35, 35 to <40, and 40+ kg/m2. (14) 
 
Since Continuous NHANES data does not contain geographical information regarding the 
individuals enrolled, and there is significant geographic variation in obesity prevalence, we used 
data from the Behavioral Risk Factor Surveillance System (BRFSS) from 2000 to 2014 to 
estimate obesity prevalence by year and regional division instituted by UNOS.(15) The BRFSS 
is a self-reported survey that allows analysis of regional variation in obesity prevalence. Entries 
Page 5 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
6 
 
 
with any missing data were excluded for this calculation. To account for missingness in height 
and weight variables in the BRFSS dataset (4.9%) through the years 2011-2014, we imputed 
the missing values using MissForest imputation method.(16, 17) We conducted imputation with 
the BRFSS data to maximize the number of values in the regional data. 
 
The national and regional US population was obtained aggregating the US population by state 
using two US Census Bureau data sets: (1) Intercensal Estimates of the Resident Population by 
Single Year of Age, Sex, Race, and Hispanic Origin for the United States: April 1, 2000 to July 
1, 2010 and (2) Monthly Population Estimates by Age, Sex, Race, and Hispanic Origin for the 
United States: April 1, 2010 to July 1, 2014.(18) The historical population data were stratified by 
year, race/ethnicity, sex, BMI, and age group. We first applied obesity proportions, including 
BMI categories, from Continuous NHANES data to the US Census Bureau population estimates 
to obtain an estimate of the national obese population. We then estimated the regional obese 
population by applying obesity estimates obtained from the BRFSS data to the regional 
population estimates from the US Census Bureau. 
 
Model Selection 
We used scatter diagrams to visualize the relationship between obese population estimates and 
NASH-related additions to the transplant waiting list at 0 to 10 year lags (i.e. a rise in obesity led 
to a rise in NASH-related waitlist additions 0 to 10 years later.) The range of lag times was 
limited by the availability of data on NASH-related waitlist additions data. The scatter diagrams 
showed a linear association between obesity and NASH additions to the waiting list at all time 
lags considered, so a linear regression model was used for analyses.  
 
National Analysis 
We examined the association between obesity and NASH additions to the waiting list using a 
linear regression model. To choose the lag time that best correlated obesity estimates and 
NASH-related waitlist additions, we evaluated predictive performance using leave-one-out 
cross-validation methodology under different lag times (0-10 years). We chose the lag time that 
minimized the internal validation root mean squared error (rMSE).(19)  
 
Based on our historical analysis, we observed the US adult obese population increased linearly 
from 2000-2014 with excellent fit, so we assumed time is a predictor for obesity. However, 
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recently published data suggest that the obesity epidemic has plateaued in recent years and it 
may stabilize over the coming decade. Thus we modeled an increase and then plateau in 
obesity prevalence based on published estimates.(20) We accomplished this by adding a 
quadratic term to our regression model of obese population as a function of time.  
   
Sensitivity Analysis on Obese Population Growth 
Given the rise in obesity, we also performed a sensitivity analysis where the obese population 
was modeled as a function of time for future projections using linear regression. 
 
Regional Analysis 
Given regional variability in obesity prevalence, we performed a secondary analysis by each 
UNOS region. We visualized the relationship between obesity estimates and NASH-related 
additions in each of the 11 UNOS regions using scatter diagrams and observed a linear 
relationship as in the national analysis, again allowing linear regression analysis. Future 
regional obesity estimates were then forecasted using time as the predictor. The linear 
regression model was based on regional obesity estimates as a continuous predictor and the 
region from which the estimates belonged as a categorical predictor.  
 
Since each UNOS region was coded as a level in a categorical predictor, the regional 
differences were expressed as differences in the intercept and slope of a linear model. The 
changes in the intercept of the model were represented by adding the value of the region to the 
original intercept of the model. Changes in the slope of the model were made by including an 
interaction term between the obese population and the region. We chose region 1 to be the 
reference level because it had the smallest estimated total obese population. In addition, the 
estimates of the obese population were divided by 
61 10×  to obtain easily legible coefficient 
estimates. We used the Wald test to assess whether the pairwise difference between the 
coefficients of the levels of the categorical predictor were statistically different from zero.(21) 
The significance of the categorical predictor and the interaction among the categorical and 
numerical predictor in the regression model were tested using the likelihood ratio test.(21)  
 
Categorical Obesity Analysis 
To better understand the impact of each BMI category on projected additions to the waitlist, we 
performed an analysis that stratified the general population and NASH additions to the waitlist 
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by BMI. The obese population by obesity class I-III (30 to <35, 35 to <40, and 40+ kg/m2) was 
estimated using linear regression with time as the predictor. We developed univariate and 
multivariate models to examine the relationship of each obesity category predicting NASH-
related waitlist additions. 
 
Projections and Stochastic Simulation  
NASH additions to the waiting list for those lagged years where data on obesity estimates were 
available were forecasted using linear regression. Prediction intervals were then obtained using 
a standard regression methodology.(22) However, in the years where we estimated the obese 
population by linear regression, we could not calculate prediction intervals of NASH-related 
waitlist additions using standard regression methodology. Therefore, point estimates and 
prediction intervals of NASH-related waitlist additions in these cases were estimated using 
stochastic simulation. This method is described in the supplementary methods section of the 
appendix.  
 
Evaluation of Model Performance 
We evaluated the model performance in two ways, the rMSE, which evaluated the derivation 
and internal validation models, and the R2, which evaluated the derivation model. The mean 
square error (MSE) is the average squared difference between an estimator (our estimates for 
NASH-related waitlist additions) and the true value of the parameter (historical NASH-related 
waitlist additions). The squared root of this measure yields the rMSE, which scales the MSE so 
the units in which it is expressed are NASH-related waitlist additions. We measured the 
performance of our models in terms of the derivation and internal cross validation rMSE. The 
derivation rMSE evaluates the performance of our models in predicting additions to the waiting 
list at years that were used to fit the models. The internal cross validation rMSE assesses the 
performance of our models in predicting the leave-out year of waitlist additions during our leave-
one-out cross-validation scheme.   
 
In addition, we assessed how well the model fit the derivation set using the adjusted coefficient 
of determination R2. The coefficient of determination R2 is a measure of how much variability in 
the data is accounted by the model. This statistic is defined as the squared of the correlation 
coefficient between the estimates and the true values. The adjusted R2 is a modification of the 
coefficient of variation to consider the number of predictors in the model.(23) It only increases if 
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the addition of a new predictor improves the fit of the model more than would be expected by 
chance and it decreases if the new predictor improves the fit of the model less than expected by 
chance. The adjusted R2 was only used to evaluate how well our models fit the data, and not 
how well our models predicted out-of-sample data.(23) 
 
All statistical analyses were performed with R (v3.2.1 The R Foundation for Statistical 
Computing, Vienna AT). 
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Results 
Trends in Obesity 
A total of 40,694 records from the Continuous NHANES dataset were included for calculation of 
obesity prevalence. The historical trend of estimates for obesity in the US is included as 
Supplemental Figure 1. Although there are minor fluctuations, the population of obese 
individuals shows a steady increase between 2000 and 2014, increasing 44.9% over that time 
period.  
NASH related additions to the waitlist also increased dramatically over the study period, from 
391 in 2000 to 1605 in 2014 (410%.) From 2000-2003 the majority of patients defined as having 
NASH were coded obese cryptogenic patients (~98%), however from 2012-2014 approximately 
86% of patients were coded as NASH rather than cryptogenic. 
 
Lag Time Selection 
NASH-related waitlist additions were best predicted by the prevalence of obesity 9 years prior. 
For example, NASH-related transplant waitlist additions in 2009 were associated with the 
proportion of obese individuals in 2000. A scatter plot describing the relationship between 
NASH-related waitlist additions and obesity estimates from 9 years prior is shown in Figure 1.  
 
This preferred model had an excellent adjusted R2 value of 0.9 (meaning 90% of variability in 
NASH-related waitlist additions could be explained by obesity estimates from 9 years prior) and 
excellent average rMSE of 50.49 in the derivation cohort and 86.49 in the validation cohort. 
Model performance under all considered time lags is included in Table 1. Coefficient estimates 
with 95% confidence intervals and corresponding p-values are included in Supplemental Table 
1.  
 
National Projection of Obesity and NASH-related Waitlist Additions 
The point estimates and 95% prediction intervals for obesity in the US from 2016 to 2030 are 
depicted in Figure 2. The obese population is expected to continue increasing, with an estimate 
of over 92 million obese adults aged 18-74 in the US by 2025. The number of NASH-related 
waitlist additions is also expected to increase by 55.4% (1,354 to 2,104) between 2016 and 
2030 (Figure 3A and 3B). 
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To assess the robustness of our model, we predicted NASH-related waitlist additions using 
different time lags of 0 to 10 years prior to waitlist addition (Supplemental Table 2). Our results 
showed projected waitlist additions by 2030 increased in all cases but varied based on the 
degree of time lag. As expected, long-term projections had more variability in the range of 
NASH-related waitlist additions: 1,354 to 1,771 in 2016, from 1,574 to 1,880 in 2020; and from 
1,694 to 2,413 in 2030.  
 
Sensitivity Analysis on Obese Population 
Supplemental Figure 2 shows the projected obese population in the US with continued linear 
growth in obesity rates. By 2030, there will be over 100 million obese adults in the US if current 
trends continue. Figure 4 shows the point estimates and 95% prediction intervals for the 
additions to the waitlist due to NASH from 2024 to 2030, assuming linear growth of obesity in 
the US. As in our base case, these estimates were obtained using stochastic simulation. If 
obesity prevalence in the US grows linearly, we would expect 3.3% more NASH additions to the 
waitlist (from 1,932 to 1,995) in 2024 and 10.6% more NASH additions to the waitlist (from 
2,104 to 2,327) in 2030, when compared to the linear growth case. With a linear model, we 
project a 71.9% increase in yearly NASH related waitlist addition from 2016 to 2030. 
 
Regional Projections 
Table 2 shows the regression coefficients (i.e. rate of change of NASH-related additions to the 
waitlist per year per 1,000,000 population) and p-values for the obese population estimates and 
UNOS region as predictors for NASH-related waitlist additions with a lag time of 9-years. The 
general obese population and the regional categorical predictor were statistically significant for 
explaining additions to the LT waiting list due to NASH (p<0.01). However, the interaction 
between general obese population and the regional categorical predictor was not significant 
(p=0.16), indicating that the rate of change or slope of the model is not significantly different 
across the regions.  The differences in the intercept of the model between region 6 and region 1 
and between region 9 and region 1 were statistically significant (both p<0.01). Furthermore, the 
intercepts in regions 6 and 9 were not statistically significant from each other (p=0.63). These 
results suggest that, given a fixed obese population, the number of additions to the waitlist due 
to NASH at regions 6 and 9 are expected to be smaller than the number of additions to the 
waitlist due to NASH at the rest of the regions. Based on our historical data, these results may 
be due to the fact that region 6 had similar obese population estimates to region 1, but less 
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additions to the waitlist. On the other hand, region 9 had approximately the same number of 
additions to the waiting list due to NASH, but it had a greater obese population than region 1. 
This suggests regional differences in center practice with regards to adding patient with NASH 
to the waiting list or underlying differences in the obese population in region 6 and 9 that either 
decrease the chances of those patients developing NASH or of NASH patients being added to 
the waitlist. 
 
BMI Categorical Analysis 
In our multivariate model using obesity categories (BMI 30 to <35, BMI 35 to <40, and BMI 40+ 
kg/m2), no individual BMI category was a significant predictor of NASH-related waitlist additions 
with a 9-year lag. In our univariate analysis, the number of individuals with BMI 30 to <35 and 
BMI 35 to 40 were both significant predictors of additions to the waitlist due to NASH (both 
p<0.01). The number of individuals in the BMI>40 category was not a statistically significant 
predictor of NASH additions to the waitlist (p=0.16). 
 
Discussion 
 NASH-related cirrhosis and HCC are the fastest growing indication for liver 
transplantation in the US and many countries worldwide.(1, 24, 25) Our analysis provides 
epidemiological insight into the relationship between obesity in the general population and the 
NASH-related additions to transplant waitlists. We demonstrated, an increase in NASH-related 
liver transplant waitlist additions is expected to occur 9 years after population-level increases in 
obesity. This has potential future implications for the US and other countries around the world 
where obesity prevalence are rising.(26) We have shown the impact on rising obesity with our 
projections of a 55.4% increase NASH related LT waitlist additions in the US over the next 15 
years, likely making NASH the dominant indication for LT in the US in coming years. Our 
sensitivity analysis shows that with future increases in obesity additions to the waitlist for NASH 
would commensurately increase. Given limited donor supply in the US, reductions in obesity on 
a population-level are particularly important to reduce the burden of NASH and NASH-related 
complications.  
We found anticipated regional variation in growth of NASH-related waitlist additions. 
UNOS regions 6 and 9 lower rates of NASH additions to the waitlist when compared to Region 
1, likely reflecting either differential patient selection or underlying differences in the population 
in these regions. In our BMI categorical analysis, we found obesity classes I and II (BMI 30 to 
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<35 and BMI 35 to <40 kg/m2) are predictive of NASH-related waitlist additions, while class III 
obesity (BMI > 40 kg/m2) was not predictive. This likely reflects the fact that many transplant 
centers do not consider extremely obese individuals for LT and patients very rarely lose 
significant amounts of weight.(27, 28) Patients who have a BMI>40 have a low likelihood of 
dropping in BMI category over a 9-year period, have a higher competing risk of non-liver related 
mortality, and thus are typically selected out of being added to the transplant waitlist.(29) 
 This study quantifies the burden of NASH on the future transplant list, which is only a 
proxy of the overall burden NASH will have on the US healthcare system. Only a minority of 
patients with cirrhosis will be eligible liver transplantation due age, obesity, other comorbidities, 
or psychosocial barriers. This may be especially salient in patients with NASH as cirrhosis tends 
to occur in obese, older patients with cardiovascular comorbidities.(30, 31) Furthermore, our 
analysis underlies the need for better diagnostic and screening tools for identifying those with 
NASH in order to provide earlier interventions, such as weight loss strategies.(32, 33) 
Unfortunately, most patients who have NASH are unaware of their diagnosis and many only 
present whe  they have hepatic decompensation or develop advanced stage HCC, at which 
time there are few options that can modify the disease course.  Thus, the overall impact of the 
increase in NASH is underestimated by this analysis, however we have provided an important 
estimation of the impact will have on LT in the US. 
 Our study has many notable strengths and weaknesses that warrant attention. We 
included 2000-2003 to increase the number of data points in the analysis, however there was 
not formal coding for NASH in the UNOS database at that time, thus we may have 
underestimated the prevalence of NASH during these early years. The correlation between 
obesity and NASH additions to the waitlist, while biologically plausible, is an association and we 
have not proven causation. Similarly, the estimated time lag of 9 years is limited by the data we 
have and longer time lags may have superior prediction ability if more data were available. The 
data used for our historical analysis and development of projections are based on single source 
data from the US Census Bureau and the OPTN, thus we lack the ability to pool data sources 
for ranges in sensitivity analyses. Our model had high R2 values and low rMSE, suggesting high 
performance, and results were consistent across sensitivity analyses and subanalyses; 
however, it is well known that model performance is lower in validation cohorts than derivation 
cohorts. We performed internal cross-validation but could not externally validate our results. 
Given lack of adequate granular data we were forced to use different methods (i.e. linear 
regression and stochastic simulation) for point estimates and prediction intervals for the NASH 
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LT addition projections. Finally, our analyses assume the current state of NASH-related care. 
Public health efforts to reduce obesity prevalence could affect our projections, as weight loss is 
associated with decreased steatosis and possible regression of fibrosis.(34, 35) However, such 
efforts have largely failed thus far as seen in our historical analysis of obesity prevalence. 
Similarly, several new investigational treatments are being studied for the treatment of NASH 
which, if effective, could significantly impact our projections.(36) 
 In conclusion, we have shown that a lag of 9 years best explains the rise in obesity in the 
US population and the rise in NASH related additions to the waitlist. Using this lag and the 
anticipated increase of obesity in the US population, we have projected a 55.4% increase in 
NASH related transplant waitlist additions. This has several public health implications for the 
transplant community and for the overall burden of NASH-related liver disease in the US.(37) It 
is especially worrisome in the setting of a plateauing donor supply, making receipt of a LT more 
difficult for those on the waitlist.(38-40) Continued public health efforts to curb obesity 
prevalence and improvement in the diagnosis of and treatment of NASH will be important to 
mitigate the overall impact of our projections. 
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Figure Legends 
 
Figure 1: Relationship between NASH-related transplant waitlist additions and obesity in the US 
using a 9-year time lag 
 
Figure 2: Prediction of Obese Population in the US 
 
Figure 3: A) Point estimates and prediction intervals of NASH-related transplant waitlist 
additions from 2016 to 2023 using linear regression B) Point estimates and prediction intervals 
of NASH-related transplant waitlist additions from 2024 to 2030 using stochastic simulation. 
 
Figure 4: Sensitivity analysis of NASH additions to the waitlist modeling the effects of linear 
growth of the national obesity rate. 
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Table 1: National Model Performance under Different Time Lags 
 
Time Lag 
(Years) 
rMSE
 
Training rMSE Validation 
Adjusted 
R-squared 
0 199.56 227.31 0.74 
1 177.23 199.27 0.78 
2 184.11 223.60 0.75 
3 204.32 257.25 0.63 
4 182.39 218.48 0.63 
5 102.66 125.05 0.85 
6 141.98 184.41 0.64 
7 179.15 274.42 0.28 
8 117.14 168.35 0.62 
9* 50.49 86.49 0.90 
10 52.72 83.78 0.82 
* - that 9-year time lag is the preferred model given lowest rMSE and highest R-squared  
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Table 2: Regional Analysis for NASH-related liver transplant waitlist additions 
  
Variables Coefficient 
95% CI 
 
Lower Lower 
Intercept -18.70 -38.99 1.59 0.070 
BMI > 30 36.23 27.96 44.51 < 0.01 
Region 1 Reference Level 
Region 2† 1.52 -28.33 31.37 0.919 
Region 3† -24.67 -71.41 22.07 0.295 
Region 4† -1.13 -29.12 26.87 0.936 
Region 5† -35.67 -81.16 9.82 0.122 
Region 6† -26.28 -44.72 -7.83 < 0.01 
Region 7† -12.16 -36.95 12.63 0.330 
Region 8† -9.10 -28.86 10.67 0.360 
Region 9† -31.04 -51.54 -10.54 < 0.01 
Region 10† -20.74 -50.61 9.13 0.170 
Region 11† -15.25 -48.71 18.21 0.365 
†The value of the intercept (-18.70) should be added to the values of the coefficients of the 
regional predictors, with the exception of the reference level, to quantify the effect of the 
different region categories in a regression equation.    
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tSupplementary	Methods	Stochastic	Simulation	
The additions to the waiting list due to NASH were simulated using numerical expressions 
derived from the predictive distribution in linear regression models. We first simulated the obese 
population.  Let ip  denote the obese population in year iy  in the dataset ( 11,2, , ).i n K   We fit a 
linear regression to the US obese population to obtain the intercept of the model, 0ˆ , the 
coefficient for the year of prediction, 1ˆ , and the mean square error of the regression model, 21ˆ .  
To simulate the obesity population at year  1 k k n , ˆkp , we used the following expression: 
 
   1 1
2
0 1 1 2
1 1
1ˆ ˆˆ 1ˆ ,kk k n
ii
y y
p y t
n y y
  

       (1) 
 
where 1ˆ  is the standard deviation of the obese population model, y  is the average year in 
which the regression was fit, 1n  is the number of years used to fit the regression model, and 1t  is 
a simulated random variable from the standard student-t distribution with 1 1 2n    degrees of 
freedom. 
 
Similarly, the additions to the waiting list due to NASH were simulated using a numerical 
expression derived from a linear regression model. Using the obese population at year i , ip , we 
predicted NASH additions to the waiting list, with a lag of L  years, at year i L  ( 21,2, , )i n K . 
We fit a linear regression model to get the intercept of the model, 0ˆ , the coefficient of obese 
population, 1ˆ , and the mean square error of the regression model, 22ˆ .  The future NASH 
additions to the waiting list at year  k L , ˆ k LN  , were obtained based on the point estimates of 
the lagged obese population, ˆkp . Future NASH additions to the waiting list at the year were 
simulated from: 
  
    2 2
2
0 1 2 2
2 1
11 ˆˆ ˆˆ ˆ ,ˆ kk L k n
ii
p p
N p t
n p p
  

       (2) 
 
where ˆkp was obtained from equation (1), 2ˆ  is the standard deviation of the NASH additions to 
the waiting list model, ip  is the obese population from the ith year used to fit the model, p  is the 
average obese population in which the regression was fit, 2n  is the number of years used to fit 
the regression model, and 2t is a simulated value from the standard student-t random variable 
with 2 2 2n    degrees of freedom. 
 
For the case of multiple predictors, equation (2) becomes  
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where  '0 01 021, , ,p p P  is a vector of new observations, 0 1 2, ,ˆ ˆ ˆˆ ,     δ  is a vector of 
regression coefficients, and P  is the design matrix of the linear model.  
 
The simulation using (1) and (2) was replicated 10,000 times.  The point estimates were obtained 
by averaging the simulated values, and 95% prediction intervals were generated by taking the 
2.5% and 97.5% quantiles of the prediction results of the replications. 
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Supplemental Figure 1 – Historical trend in obesity prevalence in the US 
 
Supplemental Figure 2 – Projected Trend in Obesity in the US with Linear Growth in 
Obesity Rates 
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tSupplemental Table 1: Regression Coefficients and P-Values for National Analysis. The 
estimates of the obese population were divided by 61 10  to obtain easily legible coefficient 
estimates.     
Variables Coeff. 
95% CI 
P  
Lower Upper 
Intercept -461.86 -1207.79 284.07 0.16 
BMI > 30 28.34 16.49 40.20 < 0.01 
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tSupplemental Table 2: Point Estimates (Prediction Intervals) of NASH Additions to the Waiting List from 2016 to 2030 under Different Time Lags 
Year 
Time Lag (Years) 
0 1 2 3 4 5 6 7 8 9 10 
2016 
1433 
(779, 
2095) 
1456 
(831, 
2084) 
1450 
(955, 
1944) 
1771 
(1123, 
2420) 
1331 
(830, 
1833) 
1518 
(1210, 
1826) 
1432 
(994, 
1870) 
1710 
(870, 
2549) 
1570 
(1107, 
2033) 
1354 
(1157, 
1550) 
1654 
(1329, 
1979) 
2017 
1470 
(825, 
2163) 
1497 
(889, 
2141) 
1618 
(935, 
2359) 
1446 
(878, 
2014) 
1803 
(1181, 
2425) 
1401 
(1107, 
1696) 
1644 
(1145, 
2143) 
1443 
(817, 
2069) 
1826 
(1231, 
2420) 
1641 
(1402, 
1881) 
1500 
(1233, 
1768) 
2018 
1508 
(859, 
2211) 
1539 
(920, 
2171) 
1660 
(975, 
2387) 
1587 
(909, 
2320) 
1502 
(967, 
2036) 
1874 
(1504, 
2244) 
1523 
(1062, 
1984) 
1603 
(860, 
2345) 
1523 
(1079, 
1968) 
1894 
(1581, 
2206) 
1862 
(1425, 
2299) 
2019 
1537 
(886, 
2222) 
1579 
(964, 
2222) 
1707 
(1025, 
2411) 
1627 
(943, 
2382) 
1633 
(995, 
2332) 
1572 
(1256, 
1888) 
2013 
(1360, 
2666) 
1511 
(840, 
2183) 
1704 
(1178, 
2231) 
1595 
(1366, 
1824) 
2179 
(1540, 
2817) 
2020 
1574 
(928, 
2271) 
1611 
(1000, 
2261) 
1753 
(1066, 
2508) 
1669 
(972, 
2431) 
1676 
(1015, 
2387) 
1701 
(1224, 
2213) 
1700 
(1181, 
2219) 
1880 
(868, 
2893) 
1601 
(1125, 
2077) 
1774 
(1498, 
2049) 
1804 
(1401, 
2207) 
2021 
1603 
(932, 
2312) 
1643 
(1032, 
2307) 
1795 
(1101, 
2540) 
1699 
(986, 
2488) 
1705 
(1036, 
2452) 
1742 
(1274, 
2258) 
1840 
(1213, 
2558) 
1645 
(865, 
2424) 
2019 
(1303, 
2736) 
1672 
(1424, 
1919) 
2028 
(1488, 
2568) 
2022 
1618 
(947, 
2320) 
1672 
(1049, 
2332) 
1825 
(1134, 
2582) 
1729 
(1008, 
2506) 
1741 
(1069, 
2493) 
1778 
(1293, 
2311) 
1878 
(1226, 
2605) 
1747 
(853, 
2727) 
1752 
(1199, 
2304) 
2085 
(1707, 
2463) 
1900 
(1440, 
2360) 
2023 
1641 
(973, 
2340) 
1693 
(1069, 
2350) 
1851 
(1145, 
2603) 
1762 
(1022, 
2539) 
1764 
(1095, 
2495) 
1811 
(1328, 
2342) 
1916 
(1243, 
2659) 
1773 
(825, 
2768) 
1865 
(1224, 
2606) 
1821 
(1531, 
2110) 
2419 
(1617, 
3220) 
2024 
1663 
(993, 
2371) 
1708 
(1067, 
2370) 
1881 
(1189, 
2626) 
1789 
(1036, 
2594) 
1799 
(1121, 
2538) 
1845 
(1362, 
2395) 
1945 
(1283, 
2707) 
1797 
(861, 
2822) 
1903 
(1222, 
2677) 
1936 
(1507, 
2426) 
2087 
(1509, 
2665) 
2025 
1672 
(1005, 
2371) 
1727 
(1095, 
2381) 
1900 
(1190, 
2659) 
1810 
(1078, 
2601) 
1818 
(1113, 
2578) 
1868 
(1376, 
2396) 
1974 
(1279, 
2757) 
1839 
(858, 
2922) 
1935 
(1226, 
2705) 
1968 
(1545, 
2448) 
2224 
(1500, 
3063) 
2026 
1686 
(1016, 
2394) 
1747 
(1118, 
2422) 
1927 
(1209, 
2716) 
1828 
(1102, 
2620) 
1836 
(1127, 
2599) 
1891 
(1380, 
2438) 
2010 
(1341, 
2794) 
1855 
(848, 
2964) 
1964 
(1253, 
2786) 
1999 
(1570, 
2498) 
2277 
(1538, 
3151) 
2027 
1687 
(1018, 
2384) 
1748 
(1138, 
2420) 
1937 
(1221, 
2722) 
1850 
(1102, 
2648) 
1860 
(1135, 
2633) 
1909 
(1401, 
2462) 
2027 
(1311, 
2827) 
1873 
(874, 
3003) 
1985 
(1270, 
2789) 
2026 
(1579, 
2523) 
2311 
(1550, 
3197) 
2028 
1697 
(1032, 
2416) 
1760 
(1127, 
2446) 
1946 
(1236, 
2709) 
1862 
(1107, 
2678) 
1869 
(1145, 
2640) 
1926 
(1424, 
2482) 
2054 
(1344, 
2871) 
1894 
(845, 
3020) 
2012 
(1259, 
2845) 
2055 
(1609, 
2580) 
2349 
(1564, 
3259) 
2029 
1690 
(1022, 
2403) 
1761 
(1124, 
2443) 
1947 
(1238, 
2719) 
1869 
(1105, 
2696) 
1880 
(1165, 
2666) 
1944 
(1447, 
2497) 
2071 
(1319, 
2882) 
1913 
(852, 
3056) 
2038 
(1271, 
2906) 
2077 
(1607, 
2600) 
2367 
(1575, 
3272) 
2030 
1694 
(1016, 
2398) 
1767 
(1120, 
2433) 
1957 
(1255, 
2729) 
1874 
(1130, 
2683) 
1889 
(1172, 
2687) 
1956 
(1459, 
2507) 
2080 
(1324, 
2895) 
1920 
(860, 
3066) 
2051 
(1284, 
2891) 
2104 
(1640, 
2635) 
2413 
(1582, 
3329) 
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